Aidixi Disitamab Vedotin Of Injection Application Scope

Aidixi Disitamab Vedotin (disitamab vedotin) is a monoclonal antibody drug conjugate (ADC) primarily used for the treatment of HER2-positive cancers. It is specifically designed to deliver a potent chemotherapy agent directly to cancer cells that overexpress the HER2 protein, which is common in various types of solid tumors.

Aidixi Disitamab Vedotin Of Injection Characteristics

Ingredients:Disitamab Vedotin (an antibody-drug conjugate composed of a monoclonal antibody targeting a specific antigen, conjugated to a chemotherapy drug)
Properties:Disitamab Vedotin is a targeted cancer therapy that works by binding to specific cancer cell surface antigens, allowing for the delivery of a cytotoxic agent directly to the tumor cells. The drug may cause cell death by interfering with the microtubule formation within the cell, preventing division and growth.
Specification:Concentration and dosage forms will vary depending on manufacturer and the treatment protocol. Typically provided in vials for intravenous infusion.

Packaging Specification:

Ingredients: Disitamab Vedotin (an antibody-drug conjugate composed of a monoclonal antibody targeting a specific antigen, conjugated to a chemotherapy drug).
Properties: Disitamab Vedotin is a targeted cancer therapy that works by binding to specific cancer cell surface antigens, allowing for the delivery of a cytotoxic agent directly to the tumor cells. The drug may cause cell death by interfering with the microtubule formation within the cell, preventing division and growth.
Specification: Concentration and dosage forms will vary depending on manufacturer and the treatment protocol. Typically provided in vials for intravenous infusion.
Storage: Store in a cool, dry place at temperatures between 2°C and 8°C (36°F and 46°F).Do not freeze. Keep the vial in the original carton to protect from light.
Effective period: The expiration date will be printed on the packaging, generally ranging from 1 to 2 years from the manufacturing date, depending on the specific product.
Approval Number: The approval number (or registration number) will depend on the country of approval, such as FDA approval in the U.S., EMA in the EU, or other relevant authorities.
Manufacturer :The specific manufacturer of Aidixi Disitamab Vedotin Injection can vary. It may be produced by pharmaceutical companies specializing in oncology treatments. Check product labeling for the exact manufacturer.

Guidelines For The Use Of Aidixi Disitamab Vedotin Of Injection

Dosage and Administration: Administer 2.0 mg/kg as an intravenous infusion over 30-90 minutes once every two weeks.
Adverse Reactions: Common adverse reactions include nausea, fatigue, decreased appetite, and peripheral neuropathy.

Medication Limitations

Contraindications: Contraindications are not specified in the available sources.
Precautions: Monitor patients for infusion-related reactions and manage symptoms accordingly. Assess for signs of peripheral neuropathy during treatment.

Aidixi Disitamab Vedotin Of Injection Interactions

Drug Interactions: No specific drug interaction studies have been conducted with disitamab vedotin.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.